D.E. Shaw & Co’s Climb Bio CLYM Stock Holding History

D.E. Shaw & Co’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,912	Closed	-$268K	–	5767
2021 Q3	$268K	Buy	+14,912	New	+$308K	﹤0.01%	4423

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's CLYM Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Climb Bio (CLYM) in Q4 2021, closing a stake of 14,912 shares — an estimated $268K sold.

D.E. Shaw & Co first reported a position in CLYM in Q3 2021 and held it in 1 quarter. The position peaked at $268K in Q3 2021. 35 funds tracked by Wall St. Rank hold CLYM as of Q4 2021.

D.E. Shaw & Co reported no remaining Climb Bio position as of Q4 2021 after selling out during the quarter.
D.E. Shaw & Co sold 14,912 Climb Bio shares in Q4 2021, an estimated $268K.
D.E. Shaw & Co first reported a position in Climb Bio in Q3 2021 and held it in 1 quarter.
D.E. Shaw & Co's Climb Bio position peaked at $268K in Q3 2021.
35 funds tracked by Wall St. Rank held Climb Bio as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.